Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis
Authors:
- 1 October 2020
- journal article
- research article
- Published by Elsevier in Joint Bone Spine
- Vol. 87 (5) , 475-479
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6Arthritis Care & Research, 2018
- Tuberculosis control in the Republic of KoreaEpidemiology and Health, 2018
- Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in AdultsNew England Journal of Medicine, 2018
- Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trialsAnnals of the Rheumatic Diseases, 2017
- Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and ChildrenClinical Infectious Diseases, 2017
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis Care & Research, 2015
- Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)The Journal of Infectious Diseases, 2012
- Critério de classificação da artrite reumatoide ACR-EULAR 2010Revista Brasileira de Reumatologia, 2010
- Adverse Effects of RifampinClinical Infectious Diseases, 1983
- The influence of age and sex on the incidence of the ‘flu’ syndrome and rifampicin dependent antibodies in patients on intermittent rifampicin for tuberculosisTubercle, 1975